RxDoctor Payments Data

Subha Sundararajan, MD

Gastroenterology · West Long Branch, NJNPI 1770741084

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 37 payments — averaging $39.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$508
  • Pfizer$198
  • AbbVie$165
  • Novo Nordisk$120
  • Janssen Scientific Affairs, LLC$118
  • Olympus America Inc.$104
  • plus $266 from 6 others

What the payments were for

  • Speaking & faculty fees$201%
  • Grants$201%
  • Food & beverage$1,43997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,479 in reported general payments places this provider in the 35th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$111,949
Medicare patients
490
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$87,798
XifaxanRifaximin14$67,594
LinzessLinaclotide25$26,075
ViberziEluxadoline12$19,321
Mesalamine39$10,184
Mesalamine ErMesalamine19$7,973
Pantoprazole Sodium269$5,305
Sucralfate39$5,079
SutabSod Sulf/Pot Chloride/Mag Sulf31$4,953
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates51$3,314
Famotidine93$1,344
Omeprazole69$1,340
Dicyclomine Hcl20$453
Esomeprazole Magnesium15$268
Lansoprazole19$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi$165$45,39637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in West Long Branch

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →